Pumactant

Drug Profile

Pumactant

Alternative Names: AdSurf; ALEC; Artificial lung expanding compound; Zofac

Latest Information Update: 04 Aug 2010

Price : $50

At a glance

  • Originator Britannia Pharmaceuticals
  • Class Phospholipids; Pulmonary surfactants
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Market Withdrawal Neonatal respiratory distress syndrome
  • No development reported Post-surgical adhesions
  • Discontinued Asthma; Respiratory tract disorders

Most Recent Events

  • 08 Sep 2009 Discontinued - Phase-II for Asthma in United Kingdom (Inhalation)
  • 08 Sep 2009 Discontinued - Preclinical for Respiratory tract disorders in United Kingdom (unspecified route)
  • 12 Nov 2004 Pumactant has been licensed to airPharma worldwide (except the UK and Ireland) for the treatment of asthma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top